More Clinuvel Pharmaceuticals Limited news
Clinuvel Pharmaceuticals LimitedASX: CUV

Preliminary assessment received from NICE

Dec 20, 2017 at 11:07 PM EST · Issued by Clinuvel Pharmaceuticals Limited

Filed with ASX · Dec 20, 2017 at 11:07 PM EST · 2 pages · English

On 6ix: 6ix.com/news/preliminary-assessment-received-from-nice

Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27↗

Clinuvel Pharmaceuticals Limited on 6ix

Story so far

  • NICE England Update on SCENESSEMay 2, 2017
  • SCENESSE - NICE England UpdateOct 18, 2016

Earlier from Clinuvel Pharmaceuticals

  • CLINUVEL provides update on SCENESSE FDA filingSep 18, 2017
  • Preliminary Final ReportAug 30, 2017
  • Amended Appendix 4C - quarterlyJul 31, 2017
  • NICE England Update on SCENESSEMay 1, 2017
  • CLINUVEL reaches agreement on German SCENESSE pricingApr 12, 2017

Later from Clinuvel Pharmaceuticals

  • CLINUVEL hosts European EPP Expert MeetingMar 18, 2018
  • CLINUVEL to take 100% ownership of VALLAURIX joint ventureMay 1, 2018
  • CLINUVEL Regulatory UpdateMay 13, 2018
  • NICE maintains position not to recommend SCENESSEMay 22, 2018
  • CLINUVEL completes SCENESSE FDA FilingJun 25, 2018
All Clinuvel Pharmaceuticals news releases↗

Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.

Follow Clinuvel Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer